Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34 þ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment. Bone marrow (BM) stroma has been implicated in the long-term survival of leukemic cells, and contributes to the expansion and proliferation of both transformed and normal hematopoietic cells. Mechanistically, we found that CML cells expressed CXCR4, and that plerixafor diminished BCR --ABL-positive cell migration and reduced adhesion of these cells to extra cellular-matrix components and to BM stromal cells in vitro. Moreover, plerixafor decreased the drug resistance of CML cells induced by co-culture with BM stromal cells in vitro. Using a functional mouse model of progressive and residual disease, we demonstrated the ability of the CXCR4 inhibitor, plerixafor, to mobilize leukemic cells in vivo, such that a plerixafor --nilotinib combination reduced the leukemia burden in mice significantly below the baseline level suppression exhibited by a moderateto-high dose of nilotinib as single agent. These results support the idea of using CXCR4 inhibition in conjunction with targeted tyrosine kinase inhibition to override drug resistance in CML and suppress or eradicate residual disease.
INTRODUCTION
In clinical trials, among chronic myeloid leukemia (CML) patients who discontinue imatinib therapy after having maintained a complete molecular response (X5 log reduction in BCR --ABL transcripts) for 2 years, the disease reemerges in 61% of cases. 1 As BCR --ABL-expressing leukemic stem cells persist in the bone marrow (BM) of CML patients with sustained undetectable molecular residual disease treated with IFN-alpha, imatinib or dasatinib, 2 such cell populations might be responsible for the reemergence of disease following the cessation of therapy. Although isolated leukemic CD34 þ cells have been shown to be insensitive to BCR --ABL tyrosine kinase inhibitors, 3 BM stromal cells, which provide survival signals that protect leukemic cells from inhibitor effects, have also been implicated in progenitor cell resistance. 2 Indeed, the quantity of leukemic stem cells that rely on stroma to survive has been found to be predictive of disease outcome. 4 Thus a better understanding of the role of the BM microenvironment in CML and its association with drug resistance is needed.
BM stroma and stroma-derived factors are thought to have a role in the long-term survival and growth of normal and leukemic cells in CML and other hematological malignancies, such as multiple myeloma and lymphoma. 5 --16 BM stroma derived granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, stem cell factor and stromal cellderived factor-1a(SDF-1a), either prevent terminal differentiation of hematopoietic stem cells or support their proliferation. 17 --23 Splenic stroma has also been implicated in increased survival of both normal and leukemic cells. 24, 25 We previously demonstrated the stromal protection of leukemic cells from the anti-proliferative effects of nilotinib, and identified stromal-derived viability factors, including IL-6 and granulocyte macrophage colony-stimulating factor, as possibly mediating protection of tyrosine kinase inhibitor-treated leukemic cells. 26 Additionally, in nilotinib-treated mice we found high leukemia burden in tissues having ample sources of hematopoiesispromoting stroma, suggesting that such tissues might support normal and malignant hematopoietic stem cell development. These studies revealed a leukemia distribution pattern consistent with that observed in imatinib-or nilotinib-treated patients.
A potential strategy to override stromal-mediated chemoresistance is to employ antagonists of the chemokine SDF-1 receptor, CXCR4, which mediates the migration of hematopoietic cells to the BM and has a key role in leukemic cell-stromal cell interactions. Of relevance, in BCR --ABL positive cells, CXCR4 expression is downregulated and CXCR4 signaling is impaired. 27, 28 BCR --ABL inhibition with either imatinib or nilotinib can upregulate the surface expression of CXCR4 to induce leukemic cell migration to the BM microenvironment leading to stromamediated chemoresistance of quiescent CML progenitor cells. 27 --29 CXCR4 antagonists may be effective in enhancing kinase inhibitorinduced apoptosis of stromal-protected leukemic cells, implicating a causal relationship between the chemokine receptor CXCR4 and SDF-1a interaction and drug-resistant leukemia. 30 Indeed, studies have shown that the CXCR4 antagonist plerixafor (AMD3100; Genzyme), 31 is effective in enhancing chemotherapy-or tyrosine kinase inhibitor-induced apoptosis of BM stroma-protected acute myeloid leukemia 32 and multiple myeloma. 12, 33 The potentiating effects of plerixafor in reducing stromaassociated minimal residual disease following tyrosine kinase inhibition in CML have been explored to a lesser extent than other hematological malignancies in vivo. The studies presented here demonstrate the ability of plerixafor to both lower leukemia burden and prolong survival of nilotinib-treated mice harboring BCR --ABL-positive disease.
MATERIALS AND METHODS
Cell lines and cell culture BCR --ABL tyrosine kinase-dependent murine 32D.p210 cells were developed as described. 34 The human CML cell-lines, K562 and KU812, were purchased from American Type Culture Collection (Rockville, MD, USA). All cell-lines were cultured with 5% CO 2 at 37 1C in RPMI (Mediatech, Inc., Herndon, VA, USA) with 10% fetal calf serum and supplemented with 1% L-glutamine. Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza and cultured according to manufacturer's instructions (Walkersville, MD, USA).
CML patient BM stroma
Human BM cells were obtained from a newly diagnosed chronic phase CML patient after obtaining informed consent on an institutional IRB approved protocol. Mononuclear cells were isolated by density gradient centrifugation through Ficoll-Plaque Plus (Amersham Pharmacia Biotech AB, Uppsala, Sweden) at 2000 r.p.m. for 30 min, followed by two washes in 1x PBS. Cells were plated in DMEM media containing 20% FBS and stroma was monitored for growth over a span of several weeks.
Flow cytometry CML cell lines (KU812F and KS62,) were washed with cold PBS, blocked for 30 min with 5% FBS in PBS on ice and treated with APC-conjugate of mouse anti-human---CXCR4 monoclonal antibody (5 mg/ml, clone 12G5), or with an isotype control, for 1 h on ice. Cells were then washed and analyzed by BD-Canto flow-cytometer (BD Biosciences, San Jose, CA, USA).
Adhesion assays
An in vitro adhesion assay coated with fibronectin, endothelial cells and BMSCs was performed as previously described. 12 Briefly, BMSCs or HUVECs were cultured overnight to confluence in 96-well plates (5 Â 10 3 cells/well) before initiating the adhesion assay. KU812F cells were treated with plerixafor (50 mM for 3 h) before performing the adhesion assay, pre-labeled with Calcein-AM (Invitrogen, Carlsbad, CA, USA), added to plates coated with fibronectin (EMD, Gibbstown, NJ, USA) with HUVECs or with BMSCs (1 Â 10 5 cells/well), and allowed to adhere for 2 h at 37 1C. Non-adherent cells were washed away, and adherent cells were detected by measuring fluorescence intensity in the wells using a fluorescent-plate reader (Ex/Em ¼ 485/520 nm).
Trans-well and Trans-endothelial migration assay Migration was determined by using the transwell migration assay (Corning Life Sciences, Acton, MA, USA), according to the manufacturer 0 s instructions and as previously described. 12 Briefly, KU812F cells were treated with 0 or 50 mM of plerixafor for 3 h before carrying out the migration assay. KU812F cells were added to the upper chamber of the basket (2 Â 10 5 cells/well), and left to migrate (for 4 h at 37 1C) towards the lower chamber, which contained no SDF-1a or 30 nM of SDF-1a. In some cases, HUVECs (5 Â 10 3 cells/basket) were incubated overnight in the upper chamber of an eight-micron pore filters (Corning Incorporated, Corning, NY, USA) before performing the adhesion assay for trans-endothelial migration assay. Those cells that migrated to the lower chambers were counted by flow cytometry.
The effect of stroma on drug resistance BMSCs (2 Â 10 4 cells/well) were plated overnight in 24-well plates. KU812F cells (2 Â 10 5 cells/ml) were treated with plerixafor (50 mM), and after 3 h were cultured with or without BMSCs with the presence or absence of plerixafor. After 3 h, cells were treated with 0 or 5 nM or nilotinib, and kept in culture for 24 h. KU812F cells were then separated from the BMSCs, washed and stained with FITC-Annexin-V and analyzed by flow cytometry.
Bioluminescent BCR --ABL model of CML 32D.p210 cells were transduced with a retrovirus encoding firefly luciferase (MSCV-Luc), and selected with G418 at a concentration of 1 mg/ml to produce the 32D.p210-luciferase (luc þ ) cell-line. Bioluminescence imaging was carried out as previously described. 35 Briefly, virus-and Mycoplasma-free cells were washed in Hank's Balanced Salt Solution (Mediatech, Inc., VA, USA), resuspended in PBS for injection, and administered via IV tail vein injection (250 ml, 8 Â 10 5 cells) into 40 female Nu/Nu NCR-nude mice (8 weeks of age; Charles River Laboratories, Wilmington, MA, USA). Following administration of 32D.p210-luc þ cells, mice were then imaged 10 days later to determine baseline bioluminescence and quantify tumor-burden as previously described. 36 Mice were subsequently treated by oral gavage for 10 days with nilotinib (75 mg/kg qd) and reimaged ('Induction Phase' of treatment); mice were at this stage considered to have minimal residual disease, with reduced tumor burden 42 logs. Mice were then randomly divided into four treatment groups ('Consolidation Phase' of treatment addressing minimum residual disease) with similar mean bioluminescence (n ¼ 8 or 9 per group): Group 1: Vehicle (PEG300 po), Group 2: plerixafor (5 mg/kg sq qd), Group 3: nilotinib (75 mg/kg po qd) and Group 4: Combination (plerixafor þ nilotinib). At the end of the study, tissues were preserved in 10% formalin. Samples, which included vital organs, were then sent for histopathological analysis.
Histopathology
Formalin-fixed tissues were dissected and processed routinely for paraffin embedding and sectioning. Six-micron sections were stained with hematoxylin and eosin.
Drug formulations for in vivo studies
Solutions of nilotinib (Novartis Pharma AG, Basel, Switzerland) were prepared just before administration, by dissolving 100 mg in 1.0 ml of NMP to give a clear solution and diluting with 9.0 ml PEG300. Plerixafor (Sigma-Aldrich, St Louis, MO, USA) was dissolved in water.
Statistical analysis
Results were reported as the mean ± s.d. for three independent experiments. Samples were compared by the Student's t-test, and results were considered significantly different for P-values less than 0.05.
RESULTS

CXCR4 expression in human CML cell lines
In comparison with isotype control, flow cytomery analysis showed that the human BCR --ABL-expressing cell lines, K562 and KU812F, expressed CXCR4 (Figure 1a) .
Plerixafor reduces BCR --ABL-positive cell adhesion and migration Direct cell interactions with BM microenvironment components have previously been shown to induce drug resistance. 12, 13 Therefore, we tested the effect of plerixafor on the adhesion of CML cells to BM microenvironment components, such as the extracellular matrix component, fibronectin (Figure 1b) , BMSCs ( Figure 1c ) and endothelial cells (Figure 1d ). We found that plerixafor decreased the adhesion of CML cells to the BM microenvironment components. Moreover, SDF-1 secreted in BM is known to induce chemotaxis of neoplastic cells to home to the protective BM. Therefore, we tested the effect of plerixafor on the chemotaxis of CML cells in response to SDF-1. Figure 1e shows that SDF-1 induced CML chemotaxis, which was inhibited by plerixafor. To complete the homing process, cells need to migrate through the walls of the blood vessels into the BM niche in a process termed 'trans-endothelial migration,' which involves both chemotaxis and adhesion to endothelial cells. Therefore, we tested the effect of plerixafor on the transendothelial migration of CML cells. Figure 1f shows that SDF-1-induced trans-endothelial migration of CML cells, which was inhibited by plerixafor.
Plerixafor reduces drug resistance of CML cells to nilotinib induced by BMSCs To demonstrate the role of the BM stroma in drug resistance in CML, we tested the effect of nilotinib on induction of apoptosis of CML cells in presence or absence of BM stroma. Figure 1 g shows that BM stroma reduced the apoptosis of CML cells induced by nilotinib. Addition of plerixafor to the co-culture system reversed the protective effect induced by the stroma, and re-sensitized the CML cells to nilotinib. The addition of plerixafor to nilotinib had no additive effect on apoptosis of CML cells when cultured alone (not in co-culture with stroma). These results suggest that disruption of the interaction of CML cells with the BM microenvironment using the CXCR4 inhibitor plerixafor sensitizes CML to nilotinib in vitro.
Plerixafor enhances tumor reduction induced by nilotinib and prolongs survival in vivo Nilotinib was highly efficacious in reducing disease burden in leukemia-engrafted mice following 10 days of administration (Figure 2a ). However, with continued treatment, animals developed resistance to nilotinib with disease burden increasing despite continued therapy (Figure 2b) . Although plerixafor had no single-agent activity, combination with nilotinib significantly delayed time to relapse, and significantly prolonged survival when compared with nilotinib monotherapy (Po0.0001) (Figures 2b  and c) . There was no significant effect of drug treatments on the body weights of the mice (Figure 2d ). As plerixafor had no monotherapeutic efficacy, there results demonstrate that plerixafor, at a well-tolerated dose, acts synergistically with nilotinib to suppress the growth of 32D.p210 leukemia.
The highest leukemia burden was compared in each of a pair of brain tissue slices from two vehicle-treated mice, two plerixafor only-treated mice, two nilotinib only-treated mice and two combination-treated mice (Supplementary Figure 1) . From the representative samples sent for histopathological analysis, control and treatment samples were generally comparable to one another and there was comparable focal infiltration into meninges of brain and spinal cord.
Mobilization of leukemic stem cells by plerixafor An independent in vivo study was performed to confirm that plerixafor mobilizes leukemic stem cells into the peripheral blood of mice as its primary mechanism of action. Mice were treated for 3 days with either vehicle control (PEG300, po qd) or plerixafor (5 mg/kg sq qd) (Figure 3 ). Luciferase activity was quantified in peripheral blood samples taken from mice on days 0 and 3 and compared between vehicle-control mice and plerixafor-treated mice. The level of luciferase activity, which is a measure of the quantity of luciferase-expressing 32D.p210 cells, in the peripheral blood of plerixafor-treated mice on day 3 was significantly higher than day 0 (P ¼ 0.03). In contrast, the level of luciferase activity in the peripheral blood of vehicle control-treated mice was comparable between days 0 and 3. This suggests mobilization of 32D.p210-luc þ cells from the BM microenvironment into the peripheral blood by plerixafor.
DISCUSSION
CXCR4 antagonists have demonstrated ability to enhance the efficacy of chemotherapeutic agents and tyrosine kinase inhibitors by disrupting the communication of malignant cells with their surrounding BM microenvironment, mobilizing these cells into the circulation, and thus rendering the cells more susceptible to the inhibitory effects of therapeutic drugs. Indeed, in vitro and in vivo studies have shown plerixafor, an antagonist/partial agonist of the alpha-chemokine receptor CXCR4 and allosteric agonist of CXCR7, 31 to be effective in mobilizing hematopoietic cells from BM and enhancing chemotherapy-or tyrosine kinase inhibitorinduced apoptosis of BM stroma-protected acute myeloid leukemia, 32,37,38 multiple myeloma 12 and CML. 29, 39 For CML, studies demonstrating the ability of plerixafor to reduce tumor burden in vivo and prolong lifespan following treatment with tyrosine kinase inhibitors have been lacking. To demonstrate potentiation of tyrosine kinase activity in CML by plerixafor, Vianello et al. 39 used measurement of the percentages of human CD19 þ cells that engrafted in the BM and spleen of mice following co-cultivation of imatinib-treated BCR--ABL-expressing cells with mesenchymal stromal cells and pre-treatment with plerixafor. They found significant reductions in engraftment for cells pretreated with plerixafor and then treated with imatinib, suggesting a restoration of the susceptibility of the cells to the ABL inhibitor by plerixafor. Thus, to date, there has been no full report of an investigation of the long-term effects of combined treatment with plerixafor and an ABL inhibitor on leukemic burden and overall survival in mice harboring BCR --ABL-positive leukemia. Our goal in this study was to see whether pharmacological targeting of drug resistance mechanisms synergizes with existing, targeted therapies as a way to enhance clinical efficacy by eliminating, or delaying the onset of, residual disease. To accomplish this, we employed a functional in vivo assay system that allows monitoring of the growth of progressive disease, as well as baseline level ('residual' disease) resulting from treatment with a moderate-to-high dose of nilotinib. This model has been successfully used previously to demonstrate synergy between the IAP inhibitor, LCL161 and nilotinib, which delayed the onset of residual disease following treatment of mice with a moderate-tohigh dose of nilotinib. 40 Here, we demonstrated the ability of stem cell mobilization to enhance the efficacy of nilotinib by suppressing leukemia recurrence following nilotinib treatment.
Consistent with the ability of plerixafor to mobilize leukemic stem cells via detachment from the BM microenvironment into the peripheral blood of mice, plerixafor diminished BCR --ABLpositive cell migration and reduced adhesion of these cells to fibronectin, BMSCs and HUVECs in vitro. Stroma reduced the apoptosis of CML cells induced by nilotinib. Addition of plerixafor to the co-culture system reversed the protective effect of the stroma and re-sensitized the CML cells to nilotinib. These results suggest that disruption of the interaction of CML cells with the BM microenvironment using the CXCR4 inhibitor plerixafor sensitizes CML to nilotinib in vitro.
A previous report 41 tested the combination of plerixafor with tyrosine kinase inhibitors imatinib and dasatinib, respectively, in a murine CML retroviral transduction/transplantation model in which minimal residual disease was not achieved despite inhibition of BCR --ABL activity. In the model utilized in this report, which mimics highly active CML, the combination of plerixafor with tyrosine kinase inhibitors did not reduce leukemia burden and instead promoted extramedullary leukemic infiltrates in vital organs including the brain. There are several differences between the murine model used in this report and that used herein that may account for the disparity in results achieved. First, we found no evidence to suggest that the combination of plerixafor with BCR --ABL inhibition in our mouse model led to extramedullary infiltration of leukemic cells. In particular, with regard to the lack of brain-infiltration, the CML model used in our study does not involve the irradiation of animals. This procedure might have damaged the blood-brain barrier in the BM transplant model employed by Agarwal et al. 41 Indeed, another study 42 confirmed that in the absence of irradiation, plerixafor does not lead to brain infiltration of BM-derived cells. In the present study and in contrast to Agarwal et al. 41 , nilotinib achieves minimal residual disease, such that an effect of plerixafor on stem cells is evident. In the absence of irradiation, toxicity resulting from extramedullary infiltration of leukemic cells was not observed. In the Agarwal et al. 41 report, imatinib has a poor PK in mice and despite being administered at 100 mg/kg BID, there was a persistence of leukemic cells in the blood and little margin to show cooperativity relating to stem cell mobilization because of this and the fact that plerixafor was likely causing toxicity due to extramedullary infiltration stemming from the irradiation. Finally, in the Agarwal et al. 41 report, dasatinib, which has a high potency but a very short plasma half-life that lowers its overall efficacy, was tested in combination with plerixafor not against minimal residual disease, but when there existed a significant burden of circulating leukemic cells. When plerixafor was administered, leukemic cells migrated into vital organs, likely leading to enhanced toxicity.
In conclusion, we demonstrated the ability of plerixafor to delay the onset of recurring BCR --ABL-positive disease in mice carrying an extremely low tumor burden following treatment with a moderate-to-high dose of nilotinib. These results support the idea of using stem cell mobilization in conjunction with targeted tyrosine kinase inhibition to override drug resistance and suppress or eradicate residual disease.
